Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Limited has had the suspension of trading in its securities on the ASX lifted, following the release of an announcement regarding its TACTI-004 (KEYNOTE-F91) Phase III trial. The trial is evaluating the company’s lead candidate, eftilagimod alfa, and the reinstatement comes after completion of a pre-specified interim futility analysis, signaling a key milestone for the program and resumption of normal market activity for investors.
The ASX decision to reinstate quotation suggests that Immutep has provided sufficient market-sensitive information related to the interim analysis outcome. This step reduces regulatory uncertainty around the stock, allows trading to resume, and underscores the clinical and commercial importance of the TACTI-004 study for the company’s growth trajectory and stakeholder confidence.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Limited (ASX: IMM) is a biotechnology company focused on developing immunotherapy drug candidates, with its lead asset being eftilagimod alfa. The company operates in the biopharmaceutical and life sciences sector, targeting advanced clinical-stage programs in partnership with major industry players and global trial networks.
Average Trading Volume: 3,345,886
Technical Sentiment Signal: Buy
Current Market Cap: A$582.1M
See more insights into IMM stock on TipRanks’ Stock Analysis page.